Image source: Getty Images
With so many shares to choose from on the ASX, it can be hard to decide which ones to buy. The good news is that brokers across the country are doing a lot of the hard work for you.
Three top ASX shares that leading brokers have named as buys this week are listed below. Here’s why they are bullish on them:
According to a note out of
Macquarie, its analysts have upgraded this corporate travel specialist’s shares to an
outperform rating with an improved price target of $20.75. The broker made the move amid signs of a strengthening recovery in travel, particularly in the United States, Australia, and New Zealand. It appears optimistic that this will continue thanks to the rapid vaccine rollout in the U.S. and falling numbers of COVID cases. This has led to Macquarie lifting its revenue forecasts for the coming years. The Corporate Travel Management share price is fetching $20.05 today.
Why Aussie Broadband, Fisher & Paykel Healthcare, Lynas, & Megaport are charging higher
James Mickleboro | January 22, 2021 11:30am |
More on:
In late morning trade the
S&P/ASX 200 Index (ASX: XJO) is on course to end a positive week on a subdued note. The benchmark index is currently down 0.1% to 6,818.2 points.
Four ASX shares that are not letting that hold them back are listed below. Here’s why they are charging higher:
The Aussie Broadband share price has jumped 7% to $2.65 after providing its guidance for the first half. According to the release, the internet service provider reported 342,634 broadband connections at the end of December. This is up 31% over the last six months and 88% since this time last year. In light of this, it expects to report half year operating earnings of $8 million to $8.5 million excluding IPO costs.
Why the Fisher & Paykel Healthcare (ASX:FPH) share price could jump higher today
James Mickleboro | January 22, 2021 8:39am |
More on:
The
Fisher & Paykel Healthcare Corp Ltd(ASX: FPH) share price could jump higher on Friday following the release of a trading update.
In New Zealand, the Fisher & Paykel Healthcare share price is currently up 6% in early trade.
How is Fisher & Paykel Healthcare performing?
Today’s update reveals that Fisher & Paykel Healthcare has continued to experience strong demand for its products in FY 2021.
According to the release, operating revenue for the nine months ended 31 December 2020 was up 73% in constant currency compared to the prior corresponding period.
The ResMed (ASX:RMD) share price is up 25% in 2020
Rhys Brock | December 16, 2020 9:45am |
More on:
This has been a frustrating year for shareholders of California-based healthcare company
ResMed Inc (ASX: RMD). Despite the ResMed share price rising almost 25% to $27.41 so far in 2020, shareholders have had to endure a fair amount of volatility to get here. It seemed like every time ResMed shares looked set to cross over the psychological $30 barrier, they ended up crashing lower.
What does ResMed do?
ResMed develops medical equipment for the treatment of respiratory conditions, with a particular focus on sleep apnoea. Early in the COVID-19 pandemic, the company announced it had ramped up production of various ventilator systems and equipment to help treat coronavirus patients suffering from respiratory complications.